BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol 2011;22:2482-8. [PMID: 21363880 DOI: 10.1093/annonc/mdr002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK. Pemetrexed in head and neck cancer: A systematic review. Oral Oncology 2013;49:492-501. [DOI: 10.1016/j.oraloncology.2013.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
2 Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858-1872. [PMID: 23444227 DOI: 10.1158/1078-0432.ccr-12-2426] [Cited by in Crossref: 201] [Cited by in F6Publishing: 134] [Article Influence: 22.3] [Reference Citation Analysis]
3 Bachour PC, Sonis ST. Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. Curr Opin Support Palliat Care 2018;12:198-210. [PMID: 29547492 DOI: 10.1097/SPC.0000000000000339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
4 Bonomo P, Loi M, Desideri I, Olmetto E, Delli Paoli C, Terziani F, Greto D, Mangoni M, Scoccianti S, Simontacchi G, Francolini G, Meattini I, Caini S, Livi L. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Critical Reviews in Oncology/Hematology 2017;120:98-110. [DOI: 10.1016/j.critrevonc.2017.10.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
5 Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin. Lung Cancer 2012;78:92-9. [DOI: 10.1016/j.lungcan.2012.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
6 Lee CC, Ho HC, Hsiao SH, Huang TT, Lin HY, Li SC, Chou P, Su YC. Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis. PLoS One 2012;7:e50163. [PMID: 23209663 DOI: 10.1371/journal.pone.0050163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
7 Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol 2016;27:1594-600. [PMID: 27177865 DOI: 10.1093/annonc/mdw204] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
8 Numico G, Franco P, Cristofano A, Migliaccio F, Spinazzé S, Silvestris N, Cante D, Sciacero P, La Porta MR, Girelli F, Ricardi U. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol 2013;85:112-20. [PMID: 22743346 DOI: 10.1016/j.critrevonc.2012.05.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
9 Specenier P, Vermorken JB. Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol 2012;2012:163752. [PMID: 22745915 DOI: 10.5402/2012/163752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
10 Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013;7:77-90. [PMID: 23723688 DOI: 10.2147/BTT.S43628] [Cited by in Crossref: 11] [Cited by in F6Publishing: 38] [Article Influence: 1.2] [Reference Citation Analysis]